Omeros | OMER - Current Liabilities


Omeros reported $85.5M in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
Adma Biologics USD 69.54M 13.05M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Cytokinetics USD 202.45M 60.31M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Immunic USD 30.08M 2.77M Sep/2025
Insmed USD 468.87M 51.66M Dec/2025
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
MacroGenics USD 43.11M 1.36M Dec/2025
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 120.59M 13.51M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Rockwell Medical USD 10.95M 259K Jun/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
United Therapeutics USD 560.6M 14.3M Dec/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025
Xoma USD 28.3M 6.81M Sep/2025